|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Welzel TM, Graubard BI, Zeuzem S, El-Serag
HB, Davila JA and McGlynn KA: Metabolic syndrome increases the risk
of primary liver cancer in the United States: a study in the
SEER-Medicare database. Hepatology. 54:463–471. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thorgeirsson SS and Grisham JW: Molecular
pathogenesis of human hepatocellular carcinoma. Nat Genet.
31:339–346. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Newell P, Villanueva A and Llovet JM:
Molecular targeted therapies in hepatocellular carcinoma: from
pre-clinical models to clinical trials. J Hepatol. 49:1–5. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ma P and Mumper RJ: Anthracycline
nano-delivery systems to overcome multiple drug resistance: a
comprehensive review. Nano Today. 8:313–331. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vanderlaag K, Wang W, Fayadat-Dilman L, et
al: Regenerating islet-derived family member, 4 modulates multiple
receptor tyrosine kinases and mediators of drug resistance in
cancer. Int J Cancer. 130:1251–1263. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Baguley BC: Multiple drug resistance
mechanisms in cancer. Mol Biotechnol. 46:308–316. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schneider E and Cowan KH: Multiple drug
resistance in cancer therapy. Med J Aust. 160:371–373.
1994.PubMed/NCBI
|
|
9
|
Pillai RS, Bhattacharyya SN, Artus CG, et
al: Inhibition of translational initiation by Let-7 MicroRNA in
human cells. Science. 309:1573–1576. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Anglicheau D, Muthukumar T and
Suthanthiran M: MicroRNAs: small RNAs with big effects.
Transplantation. 90:105–112. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Calin GA, Dumitru CD, Shimizu M, et al:
Frequent deletions and down-regulation of micro- RNA genes miR15
and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad
Sci USA. 99:15524–15529. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takamizawa J, Konishi H, Yanagisawa K, et
al: Reduced expression of the let-7 microRNAs in human lung cancers
in association with shortened postoperative survival. Cancer Res.
64:3753–3756. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Meng F, Henson R, Lang M, et al:
Involvement of human micro-RNA in growth and response to
chemotherapy in human cholangiocarcinoma cell lines.
Gastroenterology. 130:2113–2129. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Woods K, Thomson JM and Hammond SM: Direct
regulation of an oncogenic micro-RNA cluster by E2F transcription
factors. J Biol Chem. 282:2130–2134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang H, Xu C, Kong X, et al: Trail
resistance induces epithelial-mesenchymal transition and enhances
invasiveness by suppressing PTEN via miR-221 in breast cancer. PLoS
One. 9:e990672014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kutanzi KR, Yurchenko OV, Beland FA,
Checkhun VF and Pogribny IP: MicroRNA-mediated drug resistance in
breast cancer. Clin Epigenetics. 2:171–185. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stinson S, Lackner MR, Adai AT, et al:
miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes
epithelial-to-mesenchymal transition in breast cancer. Sci Signal.
4(pt5)2011.PubMed/NCBI
|
|
18
|
Yang CJ, Shen WG, Liu CJ, et al: miR-221
and miR-222 expression increased the growth and tumorigenesis of
oral carcinoma cells. J Oral Pathol Med. 40:560–566. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lu Y, Roy S, Nuovo G, et al:
Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of
tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein
and modulating mitogenic signal. J Biol Chem. 286:42292–42302.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Miller TE, Ghoshal K, Ramaswamy B, et al:
MicroRNA-221/222 confers tamoxifen resistance in breast cancer by
targeting p27Kip1. J Biol Chem. 283:29897–29903. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang CZ, Zhang JX, Zhang AL, et al:
MiR-221 and miR-222 target PUMA to induce cell survival in
glioblastoma. Mol Cancer. 9:2292010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu K, Liang X, Shen K, et al: MiR-222
modulates multidrug resistance in human colorectal carcinoma by
down-regulating ADAM-17. Exp Cell Res. 318:2168–2177. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wong QW, Ching AK, Chan AW, et al: MiR-222
overexpression confers cell migratory advantages in hepatocellular
carcinoma through enhancing AKT signaling. Clin Cancer Res.
16:867–875. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhong S, Li W, Chen Z, Xu J and Zhao J:
MiR-222 and miR-29a contribute to the drug-resistance of breast
cancer cells. Gene. 531:8–14. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Garofalo M, Di Leva G, Romano G, et al:
miR-221&222 regulate TRAIL resistance and enhance
tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell.
16:498–509. 2009.
|
|
26
|
Wittekind C: Pitfalls in the
classification of liver tumors. Pathologe. 27:289–293. 2006.(In
German).
|
|
27
|
Tio TL: The TNM staging system.
Gastrointest Endosc. 43:S19–S24. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gao Q, Qiu SJ, Fan J, et al: Intratumor
balance of regulatory and cytotoxic T cells is associated with
prognosis of hepatocellular carcinoma after resection. J Clin
Oncol. 25:2586–2593. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bruix J and Sherman M; American
Association for the Study of Liver D. Management of hepatocellular
carcinoma: an update. Hepatology. 53:1020–1022. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Llovet JM, Ricci S, Mazzaferro V, et al:
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med.
359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu L, Cao Y, Chen C, et al: Sorafenib
blocks the RAF/MEK/ ERK pathway, inhibits tumor angiogenesis, and
induces tumor cell apoptosis in hepatocellular carcinoma model
PLC/PRF/5. Cancer Res. 66:11851–11858. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Roy M, Luo YH, Ye M and Liu J: Nonsmall
cell lung cancer therapy: insight into multitargeted small-molecule
growth factor receptor inhibitors. Biomed Res Int.
2013:9647432013.PubMed/NCBI
|
|
34
|
Bai S, Nasser MW, Wang B, et al:
MicroRNA-122 inhibits tumorigenic properties of hepatocellular
carcinoma cells and sensitizes these cells to sorafenib. J Biol
Chem. 284:32015–32027. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang F, Li QJ, Gong ZB, et al:
MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular
carcinoma cells to sorafenib treatment. Technol Cancer Res Treat.
13:77–86. 2014.PubMed/NCBI
|
|
36
|
Galardi S, Mercatelli N, Giorda E, et al:
miR-221 and miR-222 expression affects the proliferation potential
of human prostate carcinoma cell lines by targeting
p27Kip1. J Biol Chem. 282:23716–23724. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang X, Yang Y, Gan R, et al:
Down-regulation of miR-221 and miR-222 restrain prostate cancer
cell proliferation and migration that is partly mediated by
activation of SIRT1. PLoS One. 9:e988332014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen Y, Zaman MS, Deng G, et al: MicroRNAs
221/222 and genistein-mediated regulation of ARHI tumor suppressor
gene in prostate cancer. Cancer Prev Res. 4:76–86. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sun T, Wang X, He HH, et al: MiR-221
promotes the development of androgen independence in prostate
cancer cells via downregulation of HECTD2 and RAB1A. Oncogene.
33:2790–2800. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li W, Tan D, Zhang Z, Liang JJ and Brown
RE: Activation of Akt-mTOR-p70S6K pathway in angiogenesis in
hepatocellular carcinoma. Oncol Rep. 20:713–719. 2008.PubMed/NCBI
|
|
41
|
Chen JS, Wang Q, Fu XH, et al: Involvement
of PI3K/PTEN/ AKT/mTOR pathway in invasion and metastasis in
hepatocellular carcinoma: association with MMP-9. Hepatol Res.
39:177–186. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Krasilnikov M, Ivanov VN, Dong J and Ronai
Z: ERK and PI3K negatively regulate STAT-transcriptional activities
in human melanoma cells: implications towards sensitization to
apoptosis. Oncogene. 22:4092–4101. 2003. View Article : Google Scholar
|
|
43
|
Saxena NK, Sharma D, Ding X, et al:
Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling
is involved in leptin-mediated promotion of invasion and migration
of hepatocellular carcinoma cells. Cancer Res. 67:2497–2507. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen KF, Chen HL, Tai WT, et al:
Activation of phosphatidylinositol 3-kinase/Akt signaling pathway
mediates acquired resistance to sorafenib in hepatocellular
carcinoma cells. J Pharmacol Exp Ther. 337:155–161. 2011.
View Article : Google Scholar : PubMed/NCBI
|
